Barnardo’s and AstraZeneca team up on the Young Health Programme to support thousands of children, young people and families in the UK

Children and young people living in poverty in the UK will gain better access to healthy food, help create a healthy living toolkit and become advocates for health policy thanks to a new partnership announced today between the children’s charity Barnardo’s and AstraZeneca, as part of the pharmaceutical company’s Young Health Programme UK. Around 2.6 million children in the UK are living in food insecure households (18% of all children)* with a lack of access to a nutritious diet which can create life-long impacts on their health.  Those benefitting from the partnership will include children and young people with experience of growing up in care, who are living alone for the first time and young…

Read More

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF), already licensed for the treatment of chronic obstructive pulmonary disease (COPD) in adults, has now been approved for use in the UK with an innovative, next-generation propellant with near-zero Global Warming Potential (GWP). This is the first medicine delivered by a pressurised metered-dose inhaler (pMDI) approved with the propellant that has 99.9% lower GWP than propellants used in currently available pMDIs. Trixeo with the next-generation propellant will have a low carbon footprint, comparable to inhaled medicines that do not require a propellant. Trixeo,…

Read More

AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential

AstraZeneca has completed the studies that support the first regulatory filings for the transition of Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) to an innovative, next-generation propellant with 99.9% lower Global Warming Potential than propellants used in currently available inhaled medicines. Breztri is a triple-combination therapy for chronic obstructive pulmonary disease (COPD) and will be the first medicine in AstraZeneca’s portfolio of pressurised-metered dose inhalers (pMDIs) to transition to the new propellant. Clinical programmes for the transition of AstraZeneca’s wider pMDI portfolio to the new propellant are underway. While pMDIs contribute…

Read More

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival. This includes new or expanded projects in Brazil, India, Vietnam, Ghana and Rwanda that will contribute to the Company’s climate action, restore nature, promote biodiversity and build ecological and community resilience, spanning over 100,000 hectares worldwide. The investment builds on AstraZeneca’s initial AZ Forest commitment, announced in 2020, to plant and maintain more than 50 million trees by the end of 2025…

Read More

AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines. This announcement coincides with the publication of the Company’s annual Sustainability Report and demonstrates progress on its flagship sustainability programme, Ambition Zero Carbon. The Report also shows that the entirety of AstraZeneca’s imported electricity now comes from renewable sources and that the Company has achieved a 59% reduction in its Scope 1 and 2 greenhouse gas (GHG) emissions since…

Read More